Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…

Genome-wide association studies have recently identified at least 15 susceptibility loci for
systemic lupus erythematosus (SLE). To confirm additional risk loci, we selected SNPs from …

Background: There is concern that exogenous female hormones may worsen disease activity
in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…

The TNFAIP3 (tumor necrosis factor alpha–induced protein 3) gene encodes a ubiquitin
editing enzyme, A20, that restricts NF-κB–dependent signaling and prevents inflammation. We …

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …

Objectives To identify factors that predict response to belimumab treatment in the phase 3
BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse …

The antiphospholipid syndrome (APS), originally defined as the combination of venous or
arterial thrombotic events, recurrent fetal loss, and, frequently, a moderate thrombocytopenia …